| GBI Research's pharma report, "Pharmaceutical | | | | Scope |
| Research and Development (R&D) - Increasing | | | | The report analyses the key measures adopted to |
| Efficency Through Information Technology and | | | | improve the R&D efficiency in the pharmaceutical |
| Externalization" provides key data, information and | | | | and biotech industry along with the major challenges |
| analysis on major pharmaceutical R&D practices | | | | that have led to a decrease in the R&D |
| at the global level in order to improve its efficiency and | | | | productivity over the last decade. The scope of the |
| effectiveness. This pharmaceutical and healthcare | | | | report includes: |
| report provides comprehensive insight into the major | | | | - Major challenges in the current pharmaceutical |
| challenges in the current pharmaceutical R&D | | | | R&D landscape. |
| landscape. It analyzes key measures and practices | | | | - Key solutions adopted by the pharmaceutical industry |
| (mergers and acquisitions, R&D restructuring, | | | | to improve the R&D productivity which include |
| outsourcing and active lifecycle management) adopted | | | | strategic mergers and acquisitions, R&D |
| by the pharmaceutical industry to tackle these | | | | restructuring, outsourcing and active lifecycle |
| challenges and improve the R&D efficiency. The | | | | management. |
| report substantiates the analysis with various case | | | | - More than 25 examples and case studies explaining |
| studies to study the effect of measure | | | | each solution and its impact on the R&D |
| post-implementation. The report also provides an | | | | productivity in a short and long term. |
| analytical insight into the potential solutions that have | | | | - Qualitative analysis of the major potential solutions |
| tremendous potential to improve the future | | | | that can improve the R&D productivity in the |
| pharmaceutical and biotech R&D productivity. | | | | future. |
| The pharmaceutical industry has witnessed a | | | | Reasons to buy |
| significant decline in R&D productivity over the | | | | The report will enhance your decision making. It will |
| past few years, which has become a matter of | | | | allow you to: |
| concern among the key stakeholders in the industry, | | | | - Identify the key R&D challenges in the industry |
| particularly the pharmaceutical companies. While the | | | | and its impact on your company's R&D |
| R&D expenditure of the industry has steadily | | | | productivity. |
| increased, the output has been declining. The increase | | | | - Understand the three different focus areas of |
| in the number of late-stage development failures is | | | | improving R&D efficiency and select the one best |
| costing the pharmaceutical industry dearly. In addition, | | | | suited to the company's long term business strategy. |
| the stringent regulatory mechanisms on the pricing and | | | | - Develop more efficient and effective solutions by |
| reimbursement of approved drugs have added to the | | | | identifying the implementation issues from the case |
| pressure. Pharmaceutical companies have tried many | | | | studies and examples covered for each solution. |
| ways to improve the R&D efficiency which | | | | - Ensure sustainable R&D growth by identifying |
| include the acquisitions of small biotechnology and | | | | long term potential solutions to improve R&D |
| pharmaceutical companies, R&D restructuring, | | | | efficiency. |
| outsourcing and better lifecycle management of their | | | | - Create an integrated and agile R&D organization |
| existing drugs in the market. However, there has been | | | | through the understanding of key technologies and |
| limited success achieved to date. | | | | other external partners in improving the R&D |
| This report is built using data and information sourced | | | | efficiency in future. |
| from proprietary databases, primary and secondary | | | | - Optimize R&D efforts by identifying the key |
| research and in house analysis by GBI Research's | | | | areas with maximum revenue potential in future. |
| team of industry experts. | | | | |